Estimation of HIV-Testing Rates to Maximize Early Diagnosis-Derived Benefits at the Individual and Population Level

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Dilernia, Dario A ^a   Monaco, Daniela C ^a   Cesar, Carina ^b   Krolewiecki, Alejandro J ^b   Friedman, Samuel R ^c   Cahn, Pedro ^b   Salomon, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; LIFE EXPECTANCY; LOWEST INCOME GROUP; MATHEMATICAL MODEL; MORTALITY; PREDICTION;

ADULT; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; EARLY DIAGNOSIS; HIV; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MODELS, BIOLOGICAL; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872022624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053193     Document Type: Article

References (56)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
3. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, et al. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370: 407-413.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725-1730.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
6. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, et al. (2008) Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 198: 59-67.
7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
8. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, et al. (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5: e11068.
9. Fisher M, (2008) Late diagnosis of HIV infection: major consequences and missed opportunities. Curr Opin Infect Dis 21: 1-3.
10. Girardi E, Sabin CA, Monforte AD, (2007) Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 46Suppl 1: S3-8.
11. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, et al. (2008) Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 24: 555-560.
12. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
13. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
14. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 296: 782-793.
15. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
16. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, et al. (2004) Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. Aids 18: 2145-2151.
17. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, et al. (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids 21: 1185-1197.
18. WHO (2008) Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector: Progress report 2008. Geneva: World Health Organization.
19. Rosenberg PS, (1995) Scope of the AIDS epidemic in the United States. Science 270: 1372-1375.
20. Gupta P, Mellors J, Kingsley L, Riddler S, Singh MK, et al. (1997) High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 71: 6271-6275.
21. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, et al. (2005) Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 21: 527-536.
22. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52-59.
23. Ameal F, Pemoff R, Cando O, Pérez H, Cahn P, (2005) Diez años de testeo para HIV en el Hospital Fernández. Actualizaciones en SIDA 13: 150-156.
24. Zala C, Rustad CA, Chan K, Khan NI, Beltran M, et al. (2008) Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina. Medscape J Med 10: 78.
25. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, et al. (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. Aids 13: F35-43.
26. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, et al. (2002) Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. Aids 16: 21-29.
27. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 458: 641-645.
28. Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, et al. (2005) Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. Aids 19: 2009-2018.
29. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 355: 1131-1137.
30. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585.
31. Pagel M, Meade A, (2006) Bayesian analysis of correlated evolution of discrete characters by reversible-jump Markov chain Monte Carlo. Am Nat 167: 808-825.
32. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, et al. (2009) Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 51: 615-623.
33. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
34. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids 22: 1897-1908.
35. Socias ME, Sued O, Laufer N, Lazaro ME, Mingrone H, et al. (2011) Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc 14: 40.
36. Badri M, Lawn SD, Wood R, (2006) Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 368: 1254-1259.
37. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, et al. (2004) Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. Aids 18: 1159-1168.
38. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, et al. (2002) Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. Aids 16: 1775-1783.
39. French N, Mujugira A, Nakiyingi J, Mulder D, Janoff EN, et al. (1999) Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. J Acquir Immune Defic Syndr 22: 509-516.
40. Sullivan AK, Curtis H, Sabin CA, Johnson MA, (2005) Newly diagnosed HIV infections: review in UK and Ireland. Bmj 330: 1301-1302.
41. Liddicoat RV, Horton NJ, Urban R, Maier E, Christiansen D, et al. (2004) Assessing missed opportunities for HIV testing in medical settings. J Gen Intern Med 19: 349-356.
42. White DA, Warren OU, Scribner AN, Frazee BW, (2009) Missed opportunities for earlier HIV diagnosis in an emergency department despite an HIV screening program. AIDS Patient Care STDS 23: 245-250.
43. Brannstrom J, Akerlund B, Arneborn M, Blaxhult A, Giesecke J, (2005) Patients unaware of their HIV infection until AIDS diagnosis in Sweden 1996-2002-a remaining problem in the highly active antiretroviral therapy era. Int J STD AIDS 16: 702-706.
44. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, et al. (2002) Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. Aids 16: 1945-1951.
45. Delpierre C, Dray-Spira R, Cuzin L, Marchou B, Massip P, et al. (2007) Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS 18: 312-317.
46. Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, et al. (2004) Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 36: 951-959.
47. Krentz HB, Auld MC, Gill MJ, (2004) The high cost of medical care for patients who present late (CD4<200 cells/microL) with HIV infection. HIV Med 5: 93-98.
48. McDonald AM, Li Y, Dore GJ, Ree H, Kaldor JM, (2003) Late HIV presentation among AIDS cases in Australia, 1992-2001. Aust N Z J Public Health 27: 608-613.
49. Hocking JS, Rodger AJ, Rhodes DG, Crofts N, (2000) Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis-characteristics of individuals. Int J STD AIDS 11: 503-508.
50. Manavi K, McMillan A, Ogilvie M, Scott G, (2004) Heterosexual men and women with HIV test positive at a later stage of infection than homo- or bisexual men. Int J STD AIDS 15: 811-814.
51. Walensky RP, Losina E, Steger-Craven KA, Freedberg KA, (2002) Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med 162: 887-892.
52. Late versus early testing of HIV-16 Sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 52: 581-586.
53. Stanley B, Fraser J, Cox NH, (2003) Uptake of HIV screening in genitourinary medicine after change to "opt-out" consent. Bmj 326: 1174.
54. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. (2007) Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315: 1583-1586.
55. Bassett IV, Walensky RP, (2010) Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis 50Suppl 3: S77-84.
56. Dilernia DA, Jones L, Rodriguez S, Turk G, Rubio AE, et al. (2008) HLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populations. PLoS One 3: e3429.